Peptide Intelligence · GLP-1

Semaglutide

Q: Is Semaglutide FDA-approved?

FDA-approved. Type 2 diabetes (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in adults with obesity or overweight (Wegovy).

Q: Can Semaglutide be compounded legally?

Approved product · compounded versions are unapproved. Branded products are FDA-approved. Compounded semaglutide is not FDA-approved or reviewed for safety, quality or effectiveness. FDA has received 990 adverse-event reports for compounded semaglutide as of May 31 2026, including dosing errors of 5–20× from multi-dose vials and unit confusion, and on Apr 30 2026 proposed excluding semaglutide from the 503B bulks list.

Q: What is the evidence for Semaglutide?

A · Human randomized trials. Large phase 3 RCT programs (STEP, SUSTAIN, SELECT). In the STEP 1 DXA substudy roughly 40% of the weight lost was lean mass.

Also: Ozempic, Wegovy, Rybelsus

FDA-approvedApproved product · compounded versions are unapprovedEvidence A · Human randomized trialsStatus as of 2026-09-02

A GLP-1 receptor agonist. It mimics a gut hormone that slows stomach emptying and signals fullness, which lowers appetite and food intake. Injected weekly (Ozempic, Wegovy) or taken as a daily tablet (Rybelsus).

We don't sell or prescribe. Wellness guidance only.

Approval status

FDA-approved

Type 2 diabetes (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in adults with obesity or overweight (Wegovy).

Compounding status

Approved product · compounded versions are unapproved

Branded products are FDA-approved. Compounded semaglutide is not FDA-approved or reviewed for safety, quality or effectiveness. FDA has received 990 adverse-event reports for compounded semaglutide as of May 31 2026, including dosing errors of 5–20× from multi-dose vials and unit confusion, and on Apr 30 2026 proposed excluding semaglutide from the 503B bulks list.

Evidence grade

A · Human randomized trials

Large phase 3 RCT programs (STEP, SUSTAIN, SELECT). In the STEP 1 DXA substudy roughly 40% of the weight lost was lean mass.

Known risks and label warnings

Boxed warning: thyroid C-cell tumors in rodents; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2
Pancreatitis; gallbladder disease; acute kidney injury from dehydration after severe GI reactions
Hypoglycemia when combined with insulin or sulfonylureas
Diabetic retinopathy complications (type 2 diabetes)
Pulmonary aspiration under anesthesia or deep sedation
Heart-rate increase (Wegovy)

Interactions people ask about

Insulin and sulfonylureas (hypoglycemia)
Oral medications with narrow absorption windows (delayed gastric emptying)

What people often measure

Framed as things to discuss with your clinician, not a protocol.

Weight, waist and (where available) lean mass over time
Protein intake and resistance-training frequency
Hydration and GI symptoms in the 24–48 h after a dose
A1c/glucose if diabetic; lipids; kidney function per clinician

Questions for your clinician

Is my pace of weight loss appropriate for my age and health?
Should I have a baseline DEXA for lean mass and bone density?
What protein target do you recommend for me?
Do I need to pause before a scheduled procedure with anesthesia?

Get the full report by email

The Semaglutide status card, monitoring list and clinician questions, printable
The pre-therapy baseline checklist: what people commonly measure before starting any injectable
A note the next time FDA or HHS acts on this compound

Send me this report and occasional Program updates. No spam, unsubscribe any time. See our privacy policy.

Wellness guidance only, not medical advice. We never sell or dispense medication.

Regulatory timeline for Semaglutide

2026-09-01
FDA updates its 'concerns with unapproved GLP-1 drugs' page
As of May 31 2026 FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, including dosing errors of 5–20×.
FDA: concerns with unapproved GLP-1 drugs
2026-04-30
FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
The proposal would end outsourcing-facility compounding of the three GLP-1s from bulk substance. Comments closed Jun 29 2026. If finalized, many compounded-GLP-1 users will face a supply transition.
FDA press announcement
2026-01-13
FDA requests removal of the suicidal-ideation warning from GLP-1 labels
After review, FDA asked manufacturers to remove the suicidal behavior and ideation warning from Wegovy, Saxenda and Zepbound labels. Ozempic never carried it.
FDA Drug Safety Communication
2024-07-26
FDA alerts on dosing errors with compounded GLP-1s
FDA warned health-care providers, compounders and patients about dosing errors from multi-dose vials and unit confusion with compounded semaglutide and tirzepatide.
FDA dosing-error alert

See the full FDA peptide tracker

Sources and review

Status as of 2026-09-02. Reviewed 2026-09-02 by Curtis Holder (product); clinical review pending; next review due 2026-12-01. Regulatory status changes; we update this page after each FDA or HHS action. Wellness guidance only, not medical advice. Med.xyz does not sell, prescribe or recommend any compound.